{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:52:03Z","timestamp":1777179123763,"version":"3.51.4"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Key R&D Program of China","award":["2020YFC0861000"],"award-info":[{"award-number":["2020YFC0861000"]}]},{"name":"National Science and Technology on New Drug Creation and Development","award":["2020ZX09201001"],"award-info":[{"award-number":["2020ZX09201001"]}]},{"name":"National Science and Technology on New Drug Creation and Development","award":["2020ZX09201012"],"award-info":[{"award-number":["2020ZX09201012"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2020-I2M-CoV19\u2013001"],"award-info":[{"award-number":["2020-I2M-CoV19\u2013001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There have been arguments on whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment alters the risk of coronavirus disease 2019 (COVID-19) susceptibility and disease severity. We identified a total of 102 eligible studies for systematic review, in which 49 studies adjusting for confounders were included in the meta-analysis. We found no association between prior ACEI\/ARB use and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the general population (adjusted odds ratio [aOR], 1.00; 95% confidence interval [CI], .94\u20131.05). The risk of mortality (aOR, .87; 95% CI, .66\u20131.04) and severe outcomes (aOR, .95; 95% CI, .73\u20131.24) were also unchanged among COVID-19 patients taking ACEIs\/ARBs. These findings remained consistent in subgroup analyses stratified by populations, drug exposures, and other secondary outcomes. This systematic review provides evidence-based support to current medical guidelines and position statements that ACEIs\/ARBs should not be discontinued. Additionally, there has been no evidence for initiating ACEI\/ARB regimen as prevention or treatment of COVID-19.<\/jats:p>","DOI":"10.1093\/cid\/ciaa1592","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:38:09Z","timestamp":1602790689000},"page":"e901-e913","source":"Crossref","is-referenced-by-count":30,"title":["The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"72","author":[{"given":"Jiuyang","family":"Xu","sequence":"first","affiliation":[{"name":"Tsinghua University School of Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqun","family":"Teng","sequence":"additional","affiliation":[{"name":"Tsinghua University School of Medicine, Beijing, China"},{"name":"Department of Cardiology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianhan","family":"Shang","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine, Beijing, China"},{"name":"Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China"},{"name":"Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China"},{"name":"Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Tsinghua University School of Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tsinghua University School of Medicine, Beijing, China"},{"name":"Department of Cardiology, Peking Union Medical College Hospital, Beijing, China"},{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"},{"name":"Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5556-8574","authenticated-orcid":false,"given":"Bin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China"},{"name":"Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"2021060106125297800_CIT0001","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"COVID-19 and cardiovascular disease","volume":"141","author":"Clerkin","year":"2020","journal-title":"Circulation"},{"key":"2021060106125297800_CIT0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2021060106125297800_CIT0003","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"2021060106125297800_CIT0004","first-page":"1769","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","volume":"323","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"2021060106125297800_CIT0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2021060106125297800_CIT0006","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(20)31131-4","article-title":"Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19","volume":"395","author":"Williams","year":"2020","journal-title":"Lancet"},{"key":"2021060106125297800_CIT0007","article-title":"Angiotensin converting enzyme 2: a double-edged sword [manuscript published online ahead of print 26 march 2020]","author":"Wang","year":"2020","journal-title":"Circulation"},{"key":"2021060106125297800_CIT0008","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"key":"2021060106125297800_CIT0009","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","volume":"116","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2021060106125297800_CIT0010","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"},{"key":"2021060106125297800_CIT0011","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"2021060106125297800_CIT0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/M20-1515","article-title":"Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review","volume":"173","author":"Mackey","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021060106125297800_CIT0013","article-title":"Do the meta-analyses provide a clean bill of health to the use of renin-angiotensin system inhibitors in COVID-19","author":"Kow","year":"2020","journal-title":"[manuscript published online ahead of print 8 August 2020]. Clin Infect Dis"},{"key":"2021060106125297800_CIT0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2021060106125297800_CIT0015","author":"World Health Organization"},{"key":"2021060106125297800_CIT0016","author":"China National Health Commission"},{"key":"2021060106125297800_CIT0017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2021060106125297800_CIT0018","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2021060106125297800_CIT0019","article-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis.","author":"Wells"},{"key":"2021060106125297800_CIT0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2021060106125297800_CIT0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2021060106125297800_CIT0022","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in high-risk patients with COVID-19","volume":"76","author":"Amat-Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2021060106125297800_CIT0023","article-title":"Non-white ethnicity, male sex, and higher body mass index, but not medications acting on the renin-angiotensin system are associated with coronavirus disease 2019 (COVID-19) hospitalis","author":"Raisi-Estabragh","year":"2020","journal-title":"MedRxiv [Preprint]. May 5,"},{"key":"2021060106125297800_CIT0024","article-title":"Covid-19 testing, hospital admission, and intensive care among 2 026 227 United States veterans aged 54\u201375 years","author":"Rentsch","year":"2020","journal-title":"MedRxiv [Preprint]. April 14,"},{"key":"2021060106125297800_CIT0025","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"2021060106125297800_CIT0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.120.15464","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea","volume":"76","author":"Son","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0027","article-title":"Role of drugs affecting the renin-angiotensin-aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province, China","author":"Yan","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0028","first-page":"e10","article-title":"Renin-angiotensin-aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study","volume":"76","author":"Andrea","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0029","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa056","article-title":"Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality","author":"Cannata","year":"2020","journal-title":"[manuscript published online ahead of print 5 June 2020]. Eur Heart J Cardiovasc Pharmacother"},{"key":"2021060106125297800_CIT0030","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives","author":"Felice","year":"2020","journal-title":"[manuscript published online ahead of print 8 June 2020]. Am J Hypertens"},{"key":"2021060106125297800_CIT0031","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"2021060106125297800_CIT0032","article-title":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy","author":"Grasselli","year":"2020","journal-title":"[manuscript published online ahead of print 15 July 2020]. JAMA Intern Med"},{"key":"2021060106125297800_CIT0033","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/HYPERTENSIONAHA.120.15324","article-title":"Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension","volume":"76","author":"Iaccarino","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0034","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/joim.13119","article-title":"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States","volume":"288","author":"Imam","year":"2020","journal-title":"J Intern Med"},{"key":"2021060106125297800_CIT0035","article-title":"Inhibitors of the renin-angiotensin-aldosterone system and Covid-19 in critically ill elderly patients","author":"Jung","year":"2020","journal-title":"[manuscript published online ahead of print 9 July 2020]. Eur Heart J Cardiovasc Pharmacother"},{"key":"2021060106125297800_CIT0036","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study","author":"Jung","year":"2020","journal-title":"[manuscript published online ahead of print 22 May 2020]. Clin Infect Dis"},{"key":"2021060106125297800_CIT0037","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera","year":"2020","journal-title":"MedRxiv."},{"key":"2021060106125297800_CIT0038","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jacc.2020.06.007","article-title":"Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection","volume":"76","author":"Lala","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2021060106125297800_CIT0039","article-title":"Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry","author":"Lopez-Otero","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2021060106125297800_CIT0040","article-title":"Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients","author":"Lorente-Ros","year":"2020","journal-title":"[manuscript published online ahead of print 26 June 2020]. Cardiol J"},{"key":"2021060106125297800_CIT0041","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","article-title":"Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?","volume":"42","author":"Sel\u00e7uk","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"2021060106125297800_CIT0042","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/cid\/ciaa492","article-title":"Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for coronavirus disease 2019","volume":"71","author":"Tedeschi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021060106125297800_CIT0043","doi-asserted-by":"crossref","DOI":"10.1007\/s11684-020-0800-y","article-title":"Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. [manuscript published online ahead of print 3 July 2020]","author":"Xu","year":"2020","journal-title":"Front Med"},{"key":"2021060106125297800_CIT0044","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"2021060106125297800_CIT0045","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1161\/HYPERTENSIONAHA.120.15622","article-title":"Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality","volume":"76","author":"Zhou","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0046","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2021060106125297800_CIT0047","doi-asserted-by":"crossref","first-page":"e0235248","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens","volume":"15","author":"Bravi","year":"2020","journal-title":"PLoS One"},{"key":"2021060106125297800_CIT0048","doi-asserted-by":"crossref","first-page":"E635","DOI":"10.1503\/cmaj.75865","article-title":"Association between angiotensin blockade and COVID-19 severity in Hong Kong","volume":"192","author":"Cheung","year":"2020","journal-title":"CMAJ"},{"key":"2021060106125297800_CIT0049","article-title":"Clinical characteristics and disease progression in early-stage COVID-19 patients in South Korea","volume":"9:1959","author":"Choi","year":"2020","journal-title":"J Clin Med"},{"key":"2021060106125297800_CIT0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4093\/dmj.2020.0105","article-title":"The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study","volume":"44","author":"Chung","year":"2020","journal-title":"Diabetes Metab J"},{"key":"2021060106125297800_CIT0051","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jamda.2020.06.018","article-title":"The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents","volume":"21","author":"De Spiegeleer","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2021060106125297800_CIT0052","article-title":"Pre-existing traits associated with Covid-19 illness severity","author":"Ebinger","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0053","article-title":"Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors","author":"Golpe","year":"2020","journal-title":"[manuscript published online ahead of print 25 June 2020]. Med Clin (Barc)"},{"key":"2021060106125297800_CIT0054","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa062","article-title":"Association between renin-angiotensin system inhibitors and COVID-19 complications","author":"Liabeuf","year":"2020","journal-title":"[manuscript published online ahead of print 12 June 2020]. Eur Heart J Cardiovasc Pharmacother"},{"key":"2021060106125297800_CIT0055","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2021060106125297800_CIT0056","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa058","article-title":"Antihypertensive drugs in COVID-19 infection","author":"Pinto-Sietsma","year":"2020","journal-title":"[manuscript published online ahead of print 5 June 2020]. Eur Heart J Cardiovasc Pharmacother"},{"key":"2021060106125297800_CIT0057","article-title":"Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19","author":"Rhee","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0058","first-page":"21","article-title":"Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19","volume":"24","author":"\u015eenkal","year":"2020","journal-title":"Anatol J Cardiol"},{"key":"2021060106125297800_CIT0059","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26183","article-title":"Impact of comorbidities on patients with COVID-19: a large retrospective study in Zhejiang, China","author":"Ye","year":"2020","journal-title":"J Med Virol"},{"key":"2021060106125297800_CIT0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/10641963.2020.1764018","article-title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors","volume":"42","author":"Zhou","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"2021060106125297800_CIT0061","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0062","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.05.052","article-title":"Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: a meta-analysis","volume":"81","author":"Pirola","year":"2020","journal-title":"J Infect"},{"key":"2021060106125297800_CIT0063","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","author":"Grover","year":"2020","journal-title":"[manuscript published online ahead of print 15 June 2020]. Eur Heart J Cardiovasc Pharmacother"},{"key":"2021060106125297800_CIT0064","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"2021060106125297800_CIT0065","first-page":"182","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension\u2014a report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","author":"Joint Committee for Guideline Revision","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"2021060106125297800_CIT0066","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-0368-x","article-title":"Interaction between RAAS inhibitors and ACE2 in the context of COVID-19","volume":"17","author":"Mourad","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2021060106125297800_CIT0067","article-title":"What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients","author":"Froldi","year":"2020","journal-title":"[manuscript published online ahead of print 5 May 2020]. J Med Virol"},{"key":"2021060106125297800_CIT0068","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur Heart J"},{"key":"2021060106125297800_CIT0069","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/HYPERTENSIONAHA.120.15782","article-title":"Effects of renin-angiotensin inhibition on ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane protease serine 2) expression: insights into COVID-19","volume":"76","author":"Wu","year":"2020","journal-title":"Hypertension"},{"key":"2021060106125297800_CIT0070","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1681\/ASN.2020050667","article-title":"Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19","volume":"31","author":"Wysocki","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2021060106125297800_CIT0071","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection","volume":"27:taaa069","author":"Chodick","year":"2020","journal-title":"J Travel Med"},{"key":"2021060106125297800_CIT0072","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"2021060106125297800_CIT0073","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"key":"2021060106125297800_CIT0074","article-title":"Therapy with agents acting on the renin-angiotensin system and risk of SARS-CoV-2 infection","author":"Gnavi","year":"2020","journal-title":"[manuscript published online ahead of print 22 May 2020]. Clin Infect Dis"},{"key":"2021060106125297800_CIT0075","article-title":"Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea","author":"Huh","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0076","article-title":"Associations with Covid-19 hospitalisation amongst 406 793 adults: the UK biobank prospective cohort study","author":"Khawaja","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0077","article-title":"Clinical and genetic characteristics of Covid-19 patients from UK Biobank","author":"Kolin","year":"2020","journal-title":"MedRxiv"},{"key":"2021060106125297800_CIT0078","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"2021060106125297800_CIT0079","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021060106125297800_CIT0080","article-title":"Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study","author":"Morales","year":"2020","journal-title":"MedRxiv"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1592\/34925498\/ciaa1592.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/e901\/38389513\/ciaa1592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/e901\/38389513\/ciaa1592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T08:09:11Z","timestamp":1622534951000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/11\/e901\/5932274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":80,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1592","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,10,20]]}}}